A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta. Both in vitro and in vivo studies showed that ETN101 treatment/administration inhibited cancer cell survival and proliferation. In animal models, ETN101 had antitumor activity when administered to animals that did not respond to conventional targeted anticancer agents.

Trial Details

NCT ID
NCT06326502
Phase
PHASE1
Sponsor
Etnova Therapeutics Corp.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ETN101
Locations (sample)
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Male and female adult at the age of ≥ 19 years old
  • Patients with radiologically or histologically, and/or cytologically confirmed advanced HCC who have confirmed disease progression on standard ther…
  • Subject with Barcelona Clinic Liver Cancer (BCLC) stage B or C; Subject with Stage B must have had progressive disease (PD) after radical resection…
  • Subject with Child-Pugh score A (5-6)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →